# Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

> **NCT05618925** · PHASE1 · RECRUITING · sponsor: **ImmunityBio, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Non Hodgkin's Lymphoma Refractory/Relapsed

## Interventions

- **DRUG:** N803
- **BIOLOGICAL:** CD19t-haNK suspension
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05618925
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-22
- **Primary completion:** 2026-05-15
- **Final completion:** 2027-03-15
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05618925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05618925, "Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05618925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*